Published On : July 2026
Not every infectious disease is diagnosed the same way, and the choice of test often depends as much on the pathogen's biology as on the clinical urgency of the case. HIV testing typically leans on antibody and antigen combination assays, while tuberculosis diagnosis still relies heavily on a mix of molecular and culture-based confirmation. Understanding which technologies dominate which disease category helps explain a large share of the demand patterns described in this site's infectious disease IVD market segmentation overview.
This page maps the four major disease categories tracked in this market, viral, bacterial, parasitic, and emerging or re-emerging infections, to the testing approaches most commonly used for each, and highlights where cross-disease multiplex testing is beginning to blur these traditionally separate categories.
This disease-by-disease view complements the platform-and-method view covered elsewhere on this site, since the same PCR instrument, for example, might be applied to a hepatitis viral load test in one laboratory and a tuberculosis molecular assay in another. For clinical program managers and public health procurement leaders, knowing which testing approach is considered standard of care for a specific disease is often more immediately useful than understanding platform mechanics in isolation, which is the gap this page is intended to close.
Different disease categories also tend to map to different buyer priorities. Viral and bacterial testing volumes are frequently anchored in routine hospital and reference laboratory ordering, while parasitic and emerging disease testing volumes lean more heavily on public health agency and multilateral program funding. Recognizing which pattern applies to a given disease category helps explain why demand for some tests grows steadily year over year while demand for others arrives in unpredictable bursts tied to outbreak response or seasonal program cycles.
Viral infections represent the largest disease-area testing category, and HIV testing illustrates why. Modern HIV diagnostic algorithms typically combine a fourth-generation antigen/antibody combination immunoassay for initial screening with a confirmatory molecular or differentiation assay, a layered approach designed to catch infection during the earliest window period, when antibody levels alone would otherwise produce a false negative.
Hepatitis testing follows a similarly layered logic. Serology establishes exposure and immune status for hepatitis B and C, while molecular viral load testing and genotyping guide treatment decisions once a chronic infection is confirmed, since genotype substantially affects treatment protocol selection for hepatitis C in particular.
COVID-19 testing established a permanent legacy on the market even as acute pandemic-era volumes have receded. Molecular RT-PCR remains the reference method for confirmatory diagnosis, while rapid antigen tests continue to serve at-home and point-of-care screening use cases where speed matters more than maximum sensitivity.
Influenza testing has moved decisively toward rapid molecular and antigen combination panels that can simultaneously distinguish influenza A, influenza B, and other common respiratory viruses, since clinical management can differ meaningfully depending on which virus is actually present. This consolidation reflects broader adoption of PCR and multiplex molecular panels across viral testing workflows, extending well beyond respiratory disease into hepatitis and HIV confirmatory testing.
A growing share of viral testing volume now comes from combination and co-infection screening rather than single-target testing alone. Prenatal and blood donor screening programs, for example, frequently combine HIV, hepatitis B, and hepatitis C testing into a single panel, reflecting both clinical efficiency and the epidemiological reality that these infections often share transmission risk factors. Respiratory virus testing has followed a similar path, with combination panels for influenza, respiratory syncytial virus, and COVID-19 becoming standard practice in many hospital and urgent care settings during peak respiratory illness seasons.
This shift toward combination testing has practical implications for laboratories and public health programs alike. It reduces the number of separate specimen collections needed per patient, improves the odds of catching co-infections that might otherwise be missed, and, from a program-planning perspective, simplifies reagent and instrument procurement by consolidating demand around fewer, broader test platforms rather than many narrow single-target assays.
Seasonality also shapes viral testing demand in ways that differ meaningfully from most bacterial or parasitic categories. Influenza and respiratory virus testing volumes rise sharply during winter months in temperate regions, requiring laboratories and manufacturers to plan capacity around a predictable annual surge rather than steady year-round demand. Hepatitis and HIV testing, by contrast, follow a much flatter demand curve tied more closely to routine screening program cadence than to any seasonal infection pattern.
Tuberculosis testing remains one of the more complex diagnostic workflows in the infectious disease category, still relying on a combination of rapid molecular assays for initial detection, sputum culture for definitive confirmation and drug-susceptibility testing, and, in some settings, older acid-fast bacilli smear microscopy where laboratory infrastructure is limited. Many of the molecular tuberculosis assays used in lower-income markets have achieved WHO prequalified diagnostic tests status, a designation that materially affects which products are eligible for large-scale public health procurement.
Sepsis diagnostics presents a different and increasingly urgent challenge, since the time between infection onset and appropriate antibiotic therapy directly affects patient survival. Rapid molecular blood culture identification panels and biomarker-based testing are both gaining ground precisely because they compress the diagnostic window from days to hours.
Sexually transmitted disease testing has shifted heavily toward multiplex molecular panels capable of simultaneously screening for chlamydia, gonorrhea, and other common pathogens from a single urine or swab sample, replacing older culture-dependent workflows that required longer turnaround and more specialized specimen handling.
Antimicrobial resistance testing is becoming an increasingly important companion to basic pathogen identification across all three bacterial disease categories covered here. Simply identifying that a patient has a bacterial infection is no longer considered sufficient in many clinical settings; understanding whether that specific pathogen is resistant to first-line antibiotics has become equally important for guiding appropriate treatment and for broader antimicrobial stewardship efforts.
This is particularly true for tuberculosis, where drug-resistant strains require an entirely different and longer treatment regimen, and for sepsis, where empirical antibiotic therapy started before pathogen identification often needs to be adjusted once resistance profiling results become available. As a result, many newer bacterial diagnostic platforms are being designed from the outset to report resistance markers alongside basic pathogen identification, rather than treating resistance testing as a separate downstream step.
Parasitic infection testing remains geographically concentrated, with malaria representing the dominant use case in regions of high transmission. Rapid antigen-based malaria tests are widely deployed at the point of care specifically because they allow treatment decisions to be made without laboratory infrastructure, while microscopy and molecular confirmation remain important for drug-resistance surveillance and species-level identification.
Neglected tropical diseases, including various helminth and protozoal infections, continue to rely on a mix of microscopy, serology, and increasingly molecular testing as manufacturers extend multiplex panel development into lower-resource settings. Growth in this category tends to track public health program funding more closely than commercial demand, since much of the testing volume is driven by government and multilateral screening initiatives rather than individual clinical orders.
Seasonal and regional variation plays an outsized role in parasitic disease testing demand compared with most other disease categories covered on this site. Malaria testing volume, for instance, typically rises sharply during rainy seasons in endemic regions, requiring testing programs and supply chains that can flex significantly across the calendar year rather than maintaining constant capacity.
This variability has pushed many public health testing programs toward simpler, more robust rapid diagnostic formats that can be stockpiled and deployed quickly when seasonal demand spikes, rather than relying exclusively on more sophisticated but logistically demanding molecular platforms that require more consistent laboratory infrastructure to operate reliably.
Emerging and re-emerging infectious diseases capture the testing demand associated with novel outbreak pathogens as well as diseases regaining clinical significance in specific regions. This category is inherently harder to forecast using standard replacement-cycle logic, since demand can spike rapidly around a single outbreak event and then subside just as quickly once containment measures take hold.
Testing approaches in this category tend to be adapted rather than purpose-built from scratch, since manufacturers typically modify existing molecular or antigen platforms to target a newly emerging pathogen rather than developing an entirely new testing chassis under outbreak time pressure. This adaptability is increasingly treated as a core design requirement for new diagnostic platforms, not an afterthought, given how quickly outbreak-driven demand can materialize.
Surveillance testing plays a critical supporting role alongside direct diagnostic testing in this category, since detecting an emerging pathogen early in an outbreak, often through wastewater or sentinel population surveillance, can meaningfully shape the public health response before individual clinical testing volumes rise sharply. Public health agencies increasingly view surveillance and diagnostic testing capacity as complementary investments rather than separate budget lines, since early surveillance signals often determine how quickly diagnostic testing capacity needs to scale in response to a genuine outbreak.
The line between disease-specific testing categories is gradually blurring as multiplex panel design becomes more sophisticated. A single respiratory panel might now screen simultaneously for influenza, COVID-19, and respiratory syncytial virus, while a single sexually transmitted infection panel might screen for several bacterial and viral pathogens at once.
This shift has practical implications for laboratories managing test menus, since a smaller number of broader panels can replace a larger number of narrower, single-target tests, simplifying inventory management and often improving diagnostic yield by catching co-infections that a single-target test would have missed entirely. For manufacturers, the strategic opportunity lies in designing panels around clinically logical syndrome groupings rather than around whichever pathogens happen to share a supply chain.
This trend also has implications for how testing menus are marketed and sold. Rather than promoting individual assays disease by disease, an increasing share of commercial activity in this market is organized around syndromic panels, grouped by clinical presentation such as febrile illness, respiratory illness, or gastrointestinal illness, rather than by a single named disease. For laboratories, this reframing simplifies ordering decisions, since a clinician can select a single panel appropriate to the patient's presenting symptoms rather than needing to guess which specific pathogen to test for in advance.
What tests are used to detect HIV infection?
HIV testing typically begins with a fourth-generation antigen/antibody combination immunoassay, followed by a confirmatory molecular or antibody differentiation test to rule out false positives and detect infection during the early window period.
How is sepsis diagnosed using IVD technology?
Sepsis diagnosis increasingly relies on rapid molecular blood culture identification panels alongside biomarker-based testing, both aimed at shortening the time between infection onset and initiation of appropriate antibiotic therapy.
Can a single test panel screen for multiple infectious diseases at once?
Yes. Multiplex molecular panels can screen for several pathogens, such as multiple respiratory viruses or several sexually transmitted infections, from a single patient sample in one test run.
What testing approaches are used for emerging infectious disease outbreaks?
Outbreak testing typically adapts existing molecular or antigen-based platforms to a new pathogen target, allowing manufacturers to bring a testing solution to market faster than developing an entirely new platform from scratch.